Share on LinkedInShare on LinkedIn

ARTICLE · 02 DECEMBER 2005

Secret Process Used for Development of Future Products not in Public Use

Applying a two-pronged test for public use as a statutory bar to novelty, the U.S. Court of Appeals for the Federal Circuit held a biotechnology invention used within the company to develop products that were never sold was not subject to a statutory bar.

United StatesIntellectual Property

Applying a two-pronged test for public use as a statutory bar to novelty, the U.S. Court of Appeals for the Federal Circuit held a biotechnology invention used within the company to develop products that were never sold was not subject to a statutory bar. Invitrogen Corp. v. Biocrest Mfg., L.P., Case Nos. 04-1273,-1274 (Fed. Cir. Oct. 5, 2005) (Rader, J.).

Genetic engineering techniques use a transformation process to introduce genetic material into cells in order to produce recombinant products. Invitrogen is the assignee of a patent that claims a process for producing transformable bacterial cells having improved competence. The district court found that the defendants infringed the patent but held the claims invalid for public use. On appeal, Invitrogen argued that internal use of the claimed process for further development of research projects did not provide a commercial advantage triggering the public use bar because the claimed process or any products derived therefrom were

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from